[1]林春尧 刘晓辉.IL-33/ST2在冠心病中的研究进展[J].心血管病学进展,2020,(2):128-131.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]
 LIN Chunyao LIU Xiaohui.IL-33/ST2 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(2):128-131.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]
点击复制

IL-33/ST2在冠心病中的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年2期
页码:
128-131
栏目:
综述
出版日期:
2020-02-25

文章信息/Info

Title:
IL-33/ST2 in Coronary Heart Disease
作者:
林春尧1 刘晓辉12
锦州医科大学大连市友谊医院研究生培养基地,辽宁 大连 116002 ;2.大连市友谊医院心内科,辽宁 大连 116002 )
Author(s):
LIN Chunyao 1LIU Xiaohui 12
Graduate Student Training Center, Dalian Friendship Hospital, Jinzhou Medical University, Dalian 116002, Liaoning, China; 2. Department of Cardiology, Dalian Friendship Hospital, Dalian 116002, Liaoning, China)
关键词:
IL-33ST2冠心病动脉粥样硬化
Keywords:
IL-33 ST2 Coronary heart disease Atherosclerosis
DOI:
10.16806/j.cnki.issn.1004-3934.2020.02.007
摘要:
白细胞介素(interleukin,IL)-33是一种近年来新发现的IL-1细胞因子家族成员,作为致瘤性抑制因子(suppression of tumorigenicity 2,ST2)的特异性功能配体被发现后,对 IL-33/ST2 系统的研究提供了新思路。IL-33与跨膜型ST2(ST2L)结合可以维持Th1/Th2平衡,具有动脉粥样硬化保护作用。研究表明,可溶性ST2(sST2)对心肌梗死和心力衰竭具有诊断和预后价值,然而IL-33的作用受到sST2的抑制。IL-33/ST2的基因变异增加了冠心病发生的风险。IL-33/ST2系统不仅有希望成为新型的心血管生物标志物,而且可能成为冠心病和心力衰竭治疗的靶点。
Abstract:
Interleukin-3 (IL-33) is a member of IL-1 cytokine family newly discovered in recent years. After being discovered as a specific functional ligand of suppressor of tumorigenicity 2 (ST2), IL-33 provides a new idea for the study of IL-33/ST2 system. IL-33 binding to transmembrane ST2 (ST2L) can maintain Th1/Th2 balance and has atherosclerotic protective effect. Studies have shown that soluble ST2 (sST2) has diagnostic and prognostic value in myocardial infarction and heart failure, but the effect of IL-33 is inhibited by sST2. Genetic variants of IL-33/ST2 increase the risk of coronary heart disease. IL-33/ST2 system is not only a promising new cardiovascular biomarker, but also a potential target for the treatment of coronary heart disease and heart failure

参考文献/References:

[1]Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J] .Immunity, 2005, 23 (5): 479-490.

[2] Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J].J Mol Cell Cardiol, 2013, 60: 16-26.

[3] Altara R, Ghali R, Mallat Z, et al. Conflicting vascular and metabolic impact of the IL-33/sST2 axis[J] . Cardiovasc Res, 2018, 114 (12): 1578-1594.

[4] 马波. 血清白介素-33水平与C-反应蛋白及冠状动脉病变程度关系的研究[D].苏州大学,2017.

[5] McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell

formation[J]. J Immuno1,2010,185(2):1222-1229.

[6] Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein ( AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibitIL-33[J]. Cytokine, 2008, 42 (3):358 -364.

[7]Demyanets S, Kaun C, Pentz R, et a l. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J]. J Mol Cell Cardiol,2013,60:16-26.

[8]Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol,2016,16:676-689.

[9] Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007, 117:1538- 1549.

[10]王建旗,史旭波,马长生,等.炎症预测和预防动脉粥样硬化性心血管事件的研究进展[J].心血管病学进展,2018,39(5):687-690.

[11]刘丹.白介素-33对高糖诱导心肌细胞凋亡的保护作用及机制研究[D].武汉大学,2016.

[12]Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis[J]. J Exp Med ,2008,205(2):339-346.

[13] Mueller T, Jaffe AS. Soluble ST2—analytical considerations[J]. Am

J Cardiol,2015,115(7):8B-21B.

[14] Ye F, Wang JA, Daugherty A, et al. Macrophage-mediated mechanisms in atherosclerosis:still tangled[J]. Curr Opin Lipidol, 2017, 28 (3):286-287.

[15]Engelbertsen D, Lichtman AH. Innate lymphoid cells in atherosclerosis[J]. Eur J Pharmacol ,2017,816:32-36.

[16]Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype[J]. EMBO Mol Med ,2012,4(10):1072-1086.

[17]Min SY, Kady J, Nam M, et al. Human ’ brite/beige’ adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice[J]. Nat Med 2016;22 (3):312-318.

[18]Zhang C, Li L, Feng K, et al. ’Repair’ treg cells in tissue injury[J]. Cell Physiol Biochem ,2017,43(6):2155-2169.

[19] Wang YP, Wang JH, Wang XL,et al. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention[J].J Cell Mol Med, 2017, 21 (11): 2677-2684.

[20] Liu X, Hu Y, Huang W,et al. Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI[J] .Int Heart J, 2019, 60 (1): 19-26.

[21] Lupón J, Cediel G, Moliner P,et al. A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score[J]. Int J Cardiol, 2019,293:148-152.

[22] Grakova EV,Kopeva KV, Teplyakov AT,et al. Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders[J]. Ter Arkh, 2019, 91(1):32-37.

[23] 燕亚茹,刘美霞.血清可溶性ST2水平与心力衰竭的相关性研究[J].心血管病学进展,2018,39(2):214-217.

[24] Lepoj?rvi ES, Piira OP, Kiviniemi AM,et al. Usefulness of highly sensitive troponin as a predictor of short-term outcome in patients with diabetes mellitus and stable coronary artery disease (from the ARTEMIS Study)[J].Am J Cardiol, 2016, 117(4):515-521.

[25]Pfetsch V, Sanin V, Jaensch A, et al. Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients:13-year follow-up of the KAROLA Study[J]. Cardiovasc Drugs Ther ,2017,31(2):167-177.

[26]O’Donoghue ML,Morrow DA,Cannon CP,et al. Multimarker risk stratification in patients with acute myocardial infarction[J].J Am Heart Assoc,2016,5(5). pii: e002586.

[27]Barbarash O, Gruzdeva O, Uchasova E,et al. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction[J].Ann Lab Med, 2016, 36(4): 313-319.

[28]Marino R, Magrini L, Orsini F,et al. Comparison between soluble ST2 and high-sensitivity troponin I in predicting short-term mortality for patients presenting to the emergency department with chest pain[J].Ann Lab Med, 2017, 37(2): 137-146.

[29] Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic value of soluble ST2 after myocardial infarction:a community perspective[J].Am J Med, 2017, 130(9): 1112.e9-1112.e15.

[30] Demyanets S, Tentzeris I, Jarai R,et al. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis[J].Cytokine, 2014, 67(2): 65-70.

[31] Tu X, Nie S, Liao Y, et al. The IL-33 —ST2L pathway is associated with coro nary artery disease in a Chinese Han population[J]. Am J Hum Genet, 2013, 93 (4):652-660 .

[32]Angeles-Martínez J, Posadas- Sánchez R, Llorente L,et al. The rs7044343 polymorphism of the interleukin 33 gene is associated with decreased risk of developing premature coronary artery disease and central obesity, and could be involved in regulating the production of IL-33[J].PLoS ONE, 2017, 12 (1): e0168828.

[33] Nie SF, Zha LF, Fan Q,et al. Genetic regulation of the thymic stromal lymphopoietin (TSLP)/TSLP receptor (TSLPR) gene expression and influence of epistatic interactions between IL-33 and the TSLP/TSLPR axis on risk of coronary artery disease[J].Front Immunol, 2018, 9: 1775.

更新日期/Last Update: 2020-04-14